Insights

Patient-Centered Engagement: Wrapping Value Around Life Science Services

In our value-driven healthcare environment, improving the quality of patients’ lives is dependent upon our ability to effectively locate and engage with patients, as well as support the therapeutic onboarding and adherence of patient populations. Delivering…

Articles

no-image
Membership Management Challenges and Best Practices

In the pharmaceutical industry, access to pricing is primarily driven by membership.Institutions like hospitals, clinics, and pharmacies sign up as members of a Group Purchasing Organization (GPO) to be eligible to purchase products at a discounted…

no-image
Pharmaceutical Contracting from Volume to Value

Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies,…

white paper-insights
Medicaid Drug Classification: Civil Monetary Penalties

On April 18, 2019, the “Medicaid Services Investment and Accountability Act of 2019” was signed into law, bringing with it a significant change to the oversight and management of the Medicaid Drug Rebate Program (MDRP). Effective…

no-image
Gene Therapy for Rare Disorders

With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?

white paper-insights
Setting a Patient Engagement Framework and Proving Value

Is your culture patient-centric? It needs to be because today’s patients are motivated information seekers – empowered decision-makers with respect to their treatment. Their voice is key to your success.

no-image
Insights from AMCP 2019

EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and…

Balancing Access

Value propositions need to justify product pricing by focusing on the burden of severe illnesses and how the products address unmet needs.

Develop Patient Support Programs Focused on Patients

We have to get intimate with patient populations and advocacy groups to build best-in-class patient support programs from the start.

Providing a Patient-Driven Experience

As the “patient-as-consumer” culture enables patients to consider all their varied care options, they increasingly want to be involved not only by participating in clinical trials, but also by accelerating product development and the availability of…

Could CMS Policies Impact Investments in CAR T-cell Therapies and Other Innovative Treatments?

Clinical pathways that include CAR T-cell therapy as an option must integrate appropriate guidance on its use and settings of care.